SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Tularik Inc. (TLRK)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (129)1/17/2002 1:30:58 AM
From: Miljenko Zuanic   of 598
 
"">> has enrolled <<
Correct, which means that they are NOT doing dose intensification.""

Yes, they have enrolled all pts for this PII trial. And they planed to report results at ASCO.
However, this does not give all answers on possibility for combination study(ies), how to designee pivotal, will FDA accept pivotal program or ask for more PII trial. If they have positive response from FDA they may proceed with pivotal.

For other indications they are still doing doses response/safety studies with T67.

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News